Cumulative probability estimates of PML

According to number of natalizumab infusions and anti-JCV antibody index score in patients with and without previous immunosuppressant use

Patients without previous immunosuppressant use, per 10,000 patients

Patients with previous immunosuppressant use, per 10,000 patients

Number of infusions	Index ≤0,9	Index > 0,9 to ≤ 1,5	Index > 1,5	
0	0,0	0,0	0,0	0,0
12	1 in 100,000*	6 in 100,000***	2 in 10,000	4 in 10,000
24	6 in 100,000**	3 in 10,000	11 in 10,000	8 in 10,000
36	2 in 10,000	11 in 10,000	37 in 10,000	44 in 10,000
48	6 in 10,000	31 in 10,000	104 in 10,000	126 in 10,000
60	11 in 10,000	55 in 10,000	182 in 10,000	213 in 10,000
72	16 in 10,000	85 in 10,000	280 in 10,000	270 in 10,000

The confidence interval has been removed in this table.
*, **, *** The probability for these 3 patient groups in regard to in 10,000 looks like this:
*0,1 in 10,000
** 0,6 in 10,000
*** 0,6 in 10,000

Data are cumulative probability estimates (95% CI) for the pooled cohort. Lengths of natalizumab exposure are given as number of infusions.

Adapted from Ho et al, 2017

Reference: Ho et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies. Lancet Neurology; 2017:16,11; 925–933